Here we indicated CSO could reduce the tumor-induced elevation of MuRF1 in muscle tissue through inhibiting phosphorylation of the NF-κB p65 at the Ser536 site, which also coincides with previous studies revealing the anti-tumor mechanism of KLT [20, 43]. The gene discussed is NFKB1; the disease is neoplasm.